The research subject advocate at the University of Hawai'i Clinical Research Center: an added resource for protection of human subjects.
In early 2001 the National Institutes of Health (NIH) created the Research Subject Advocate (RSA) position as an additional resource for human subjects protection at NIH-funded Clinical Research Centers (CRCs) to enhance the protection of human subjects participating in clinical research studies. The purpose of this article is to describe the RSA position in the context of clinical research, with a particular emphasis upon the role of the RSA in one of the five CRCs funded by the NIH Research Centers in Minority Institutions (RCMI) program. Through participation in protocol development, informed consent procedures, study implementation and follow-up with adverse events, the RSA works closely with research investigators and their staff to protect study participants. The RSA also conducts workshops, training and education sessions, and consultation with investigators to foster enhanced communication and adherence to ethical standards and safety regulations. Although it is too early to provide substantive evidence of positive outcomes, this article seeks to illuminate the value of the RSA position in ensuring that safety of research participants is accorded the highest priority at CRCs. Based upon initial results, we conclude that the RSA is an effective mechanism for achieving the NIH's goal of maintaining the utmost scrutiny of protocols involving human subjects.
Easa
David
D
University of Hawaii, John A. Burns School of Medicine, Honolulu, HI 96821, USA. david@kapiolani.org
Kim
Kari
K
Kato
Kambrie
K
Ho
Tammy
T
Balaraman
Venkataraman
V
Medina
Louise
L
Hammatt
Zoë
Z
Shomaker
T Samuel
TS
D000046:Academic Medical Centers; D006254:Hawaii; D006805:Human Experimentation; D006801:Humans; D010344:Patient Advocacy; D017751:Safety Management